DUBLIN – Crispr Therapeutics AG raised $64 million in new funding, bringing in two heavyweight strategic investors, London-based Glaxosmithkline plc, through its SR One venture capital arm, and Celgene Corp., to advance its development of novel therapies based on Crispr-Cas9, the genome editing technology that has taken the academic world by storm since its emergence in 2012.